Breaking News
September 25, 2018 - Lung cancer patients treated with invasive surgery more likely to become chronic opioid users
September 25, 2018 - Oxford VR raises £3.2m to boost innovation in VR for mental health problems
September 25, 2018 - Gene therapy approach could help treat mitochondrial diseases
September 25, 2018 - Few Yogurt Products Qualify As Low-Sugar
September 25, 2018 - Eye disease can cause blindness, and it’s on the rise
September 25, 2018 - Pawnshop density linked to gun-related suicides, Stanford study finds
September 25, 2018 - Pioneering procedure for common prostate condition offered by The London Clinic
September 25, 2018 - Number of people with respiratory diseases likely to increase if UK air pollution remains unchecked
September 25, 2018 - FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial
September 25, 2018 - New program to reduce harmful stress effectively improves mood in cancer patients
September 24, 2018 - Florence’s Lingering Threat: Mold – Drugs.com MedNews
September 24, 2018 - For professional baseball players, faster hand-eye coordination linked to batting performance
September 24, 2018 - Bill for later school start times is defeated, but Stanford sleep specialist isn’t
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Successful recovery from addiction means more than achieving abstinence
September 24, 2018 - New nanoplatform technology may reverse drug-resistance in renal cell carcinoma
September 24, 2018 - October 1918 marks the centenary of Spanish Flu that claimed more lives than World War I
September 24, 2018 - LGBT community reports more number of poor mental health days than general population
September 24, 2018 - New research suggests power of zebrafish as tool for cancer drug discovery
September 24, 2018 - New study finds height as possible risk factor for developing varicose veins
September 24, 2018 - Researchers compare weight loss results of online and in-person diabetes prevention program
September 24, 2018 - New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment
September 24, 2018 - Drug combination offers more effective care for patients suffering miscarriage
September 24, 2018 - Tallness linked to varicose veins, Stanford study says
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Ecstasy drug makes octopuses more social
September 24, 2018 - Immediate compression therapy could cut risk of complications after deep-vein thrombosis
September 24, 2018 - Transcatheter mitral valve repair reduces mortality for patients with mitral regurgitation
September 24, 2018 - First intracranial aneurysm patients treated with BRAVO Flow Diverter after CE mark approval
September 24, 2018 - ‘Physicians of the mouth’? Dentists absorb the medical billing drill
September 24, 2018 - People more likely to believe those with confident tone of voice than with accent
September 24, 2018 - Harmony Biosciences Presents 5-Year Data On Pitolisant At International Narcolepsy Symposium
September 24, 2018 - Blood test may identify gestational diabetes risk in first trimester
September 24, 2018 - Height may be risk factor for varicose veins | News Center
September 24, 2018 - King’s commemorates opening of new NMR facility with one-day symposium
September 24, 2018 - Eisai receives approval for partial label change of DC Bead device for transcatheter arterial embolization
September 24, 2018 - High-resolution genomic map gives scientists unprecedented view of brain development
September 24, 2018 - Researchers find impact of neurobehavioral symptoms on employment in adults with TBI
September 24, 2018 - Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD
September 24, 2018 - First evaluation of benefits, harms of Alzheimer’s screening for family members of older adults
September 24, 2018 - Ancora Heart announces positive data of study evaluating AccuCinch Ventricular Repair System
September 24, 2018 - Children of mothers using cannabis may start using it at an earlier age, finds study
September 24, 2018 - Gilead Sciences plans to launch authorized generic versions of Epclusa and Harvoni in the US
September 24, 2018 - Most patients who underwent transcatheter valve replacement experience prosthesis-patient mismatch
September 24, 2018 - Lumos acquires license for LUM-201 drug that promotes secretion of growth hormone
September 24, 2018 - New study provides basis for Air Canada to change its facial hair policy for aircrew
September 24, 2018 - Infant walkers lead to thousands of emergency visits for babies
September 24, 2018 - Genes predicting person’s height may provide clues about causes of varicose veins
September 24, 2018 - EPA Plan Will Maintain Carbon Emissions From Power Plants
September 24, 2018 - Characterizing pig hippocampus could improve translational neuroscience
September 24, 2018 - Element3 Health reports social and mental engagement play key role in overall health
September 24, 2018 - Paralympic medalists support Fight for Sight’s unique virtual event
September 24, 2018 - ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma
September 24, 2018 - Public awareness of urological conditions found to be alarmingly low across Europe
September 24, 2018 - Fitter Folks Suffer Milder Strokes: Study
September 24, 2018 - Novel botulinum toxin compound relieves chronic pain
September 24, 2018 - CHMP recommends approval of Gilenya for treatment of multiple sclerosis in children, adolescents
September 24, 2018 - National Friendly’s private medical insurance is a hit with women living in the South East
September 24, 2018 - Academics receive prestigious awards for achievements in blood pressure research
September 24, 2018 - Obese pregnant women can restrict weight gain safely with proper nutrition guidance
September 24, 2018 - CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer
September 24, 2018 - China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma
September 24, 2018 - A new approach for finding Alzheimer’s treatments
September 24, 2018 - USC research uncovers previously unknown genetic risk factor for dementia
September 24, 2018 - Study examining mental health among students finds significant disparities in treatment across race
September 24, 2018 - Breakthrough discovery paves way for future test to identify drowsy drivers
September 24, 2018 - Transcatheter mitral-valve repair in patients with heart failure
September 24, 2018 - Study opens new avenues for treatment of Laing distal myopathy
September 24, 2018 - Stroke Facts | cdc.gov
September 24, 2018 - Sarcolipin tricks muscle cells into using more energy, burning fat
September 24, 2018 - Enrollment in opioid controlled substance agreement reduces primary care visits
September 24, 2018 - UTA researchers patent new smart seat cushion technology that helps prevent painful ulcers
September 24, 2018 - Second HPV-Related Primary Cancers Common in Survivors
September 24, 2018 - How a virus destabilizes the genome
September 24, 2018 - Old letters provide insight into Spanish flu pandemic horror
September 23, 2018 - Smart textile-based soft robotic exosuit helps wearers save energy and traverse difficult terrain
September 23, 2018 - New research hub to drive radical change in development and manufacturing of vaccines
September 23, 2018 - AHA: For Hispanics, Neighborhood May Be Key Factor in Heart Disease Risk
September 23, 2018 - Excessive airway nerves tied to more severe asthma symptoms, study finds
September 23, 2018 - Study highlights need to remain vigilant in maintaining key infection control processes
Lesser-known CRS-HIPEC treatment for cancers that have spread to abdominal cavity

Lesser-known CRS-HIPEC treatment for cancers that have spread to abdominal cavity

image_pdfDownload PDFimage_print

While cancer treatment advances are being made in the areas of precision medicine and immunotherapy, a unique combination of traditional therapies can also provide some cancer patients a treatment option that may provide significant benefit. For instance a lesser-known treatment combining cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is being increasingly used to treat cancers that have spread to the abdominal cavity – a condition known as peritoneal metastases. This treatment strategy involves the surgical removal of metastatic cancer deposits followed by heated chemotherapy given within the abdominal cavity designed to obliterate the remaining invisible cancer cells that may be present in the tissues.

Rutgers Cancer Institute of New Jersey is one of the few centers in the region whose surgeons have vast expertise in managing patients’ disease through this unique treatment. Having recently expanded its surgical and research focus on cancers of the abdominal cavity, the Institute has named H. Richard Alexander, MD, FACS, as its new chief surgical officer. Dr. Alexander, who is also a professor of surgery at Rutgers Robert Wood Johnson Medical School, has been pioneering the development of CRS-HIPEC through its evolution over the past two decades. He shares more about the procedure.

Q: Tell us more about CRS-HIPEC.

A: CRS and HIPEC are really two complementary components of treatment. CRS is the systematic removal of all visible cancer deposits in the abdominal cavity, but it is ineffective at addressing invisible or microscopic tumor deposits that are present in the abdominal tissues. HIPEC is a strategy of delivering an intensive dose of chemotherapy right to the tissues that are at risk of harboring invisible cancer cells. HIPEC is administered in the operating room right after the CRS is completed. It usually takes about 90 minutes and may be an optimal way of ensuring that the chemotherapy is distributed to all the tissues in the abdomen. It also takes advantage of the fact that many chemotherapy agents have an enhanced effect on killing cancer cells under hyperthermic conditions — when the temperature in the tissues is slightly increased.

Q: What kind of cancers can it treat?

A: The CRS and HIPEC combination has been used to treat patients with a variety of cancers that have the ability to spread diffusely throughout the abdominal cavity such as colorectal cancer, appendiceal cancer, ovarian cancer, mesothelioma, and in some cases gastric or other cancers. There is growing evidence to support the use of CRS and HIPEC for some conditions. However, its use in some settings is more controversial.

Q: Who is the best candidate for this procedure?

A: A surgical oncologist with expertise in CRS and HIPEC is the best person to discuss whether or not this treatment is an option for someone who has abdominal spread of cancer. The decision to proceed with the procedure should be a collaborative one involving the patient, the family, and all the cancer specialists involved. Ideally, it should be considered part of a thoughtful strategy that may include additional treatment before and after the procedure to assist in controlling the cancer. A patient should be in fundamentally good medical condition and not have other medical problems that might make the procedure unacceptably risky. Sometimes, additional testing may be necessary prior to the procedure.

Q: Why is this procedure not widely offered at all hospitals or cancer treatment centers?

A: CRS-HIPEC requires specialized expertise and equipment not available at all treatment centers. It is widely acknowledged that complications and the risk of the procedure are minimized when performed by surgeons and at medical centers with experience in this area, such as Rutgers Cancer Institute of New Jersey.

Q: What is the benefit of receiving CRS-HIPEC at a National Cancer Institute-designated Comprehensive Cancer Center like Rutgers Cancer Institute?

A: The reality is that patients who undergo the CRS-HIPEC procedure, even when it is considered successful, are at a higher risk of experiencing a recurrence at some point during follow-up surveillance. Because of that it is beneficial for a patient to be cared for at a facility where second-line treatment options and access to clinical trials are available. ​

Source:

https://www.cinj.org/turning-heat-chemotherapy

Tagged with:

About author

Related Articles